Financial Incentives and Motivational Intervention to Improve Gastric Cancer Screening in China
NCT06384300 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5000
Last updated 2024-04-25
Summary
Gastric cancer, also known as stomach cancer, is a serious disease that affects the stomach. It's one of the most common types of cancer, and sadly, many people die from it each year. But there's hope! We can catch gastric cancer early with a special test called endoscopy. This test helps doctors find cancer or pre-cancerous changes in the stomach early, when it's easier to treat. However, not enough people get this test, especially in places where healthcare isn't easily available. That's why we're doing this study.
We want to find out if we can encourage more people to get the endoscopy test for gastric cancer. We're going to try two different ways to encourage people to get the test. First, we'll give some people money or other incentives to help cover the costs of getting the test. Second, we'll give others information and support to help them understand why the test is important and how it can help them.
We'll be doing this study in two provinces in China, where gastric cancer is a big problem. We'll ask thousands of people to join the study, and we'll randomly assign them to one of the two groups. Then, we'll see if more people in one group get the endoscopy test compared to the other group.
Our hope is that by finding out what works best, we can help more people catch gastric cancer early and get the treatment they need. This could save many lives and make a big difference in fighting this disease.
Conditions
Interventions
- OTHER
-
Financial Incentives
In the financial incentive group, participants will receive reimbursement for transportation, accommodation, and food costs, along with RMB 200 (about 30 US dollar) to compensate for potential income loss due to endoscopy, provided they undergo the endoscopy.
- OTHER
-
Motivational Intervention
For the motivational intervention group, researchers will provide detailed information about the social norms surrounding endoscopy screening, including the prevalence of screening participation, the potential risks of gastric cancer, and the health benefits of screening.
- OTHER
-
Mixed Intervention
Participants in the mixed intervention group will receive both financial incentives and motivational intervention.
Sponsors & Collaborators
-
Peking University
lead OTHER
Principal Investigators
-
Li Yang, PhD · Peking University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-08-01
- Primary Completion
- 2027-01-31
- Completion
- 2027-07-31
More Related Trials
-
Clinical Significance of Circulating Tumor Cells (CTCs) in Blood of Patients With Advanced/Metastatic Gastric Cancer
NCT01625702 ·Status: COMPLETED ·Phase: NA
-
Correlation of Psychological Distress and Immune Checkpoint Inhibitors in Gastric Cancer
NCT07003334 ·Status: RECRUITING
-
Nutrition-support-team Based Intervention in Patients With Advanced Gastrointestinal Cancer
NCT03631537 ·Status: UNKNOWN ·Phase: NA
-
The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study
NCT02583659 ·Status: UNKNOWN
-
Clinical Study of Weifuchun Treatment on Gastric Cancer
NCT05888675 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial
NCT06943794 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Real World Study of Immune Checkpoint Inhibitors for Advanced Gastric Cancer
NCT04086888 ·Status: UNKNOWN
-
Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Local Advanced Gastric Cancer
NCT00992199 ·Status: UNKNOWN ·Phase: PHASE2
-
The Association Between Microplastics and Macrogenomics and Metabolomics in Gastric Cancer
NCT06856382 ·Status: ACTIVE_NOT_RECRUITING
-
Prospective Evaluation and Molecular Profiling in People With Gastric Tumors
NCT03027427 ·Status: COMPLETED
-
Assessing Quality of Life of Patients With Stomach Cancer
NCT00020826 ·Status: COMPLETED
-
Application Value of CTCs Detection for Advanced Gastric Cancer Patients
NCT03156777 ·Status: UNKNOWN
-
A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
NCT01839500 ·Status: COMPLETED
-
Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study
NCT05721651 ·Status: RECRUITING ·Phase: PHASE2
-
Methylation Analysis of Circulating Tumor DNA in Gastric Cancer
NCT04511559 ·Status: UNKNOWN
-
Clinical Study of Weifuchun Treatment on Precancerous Lesions of Gastric Cancer
NCT03814629 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Microbiota and Metabolomics of Intestinal Type of Gastric Cancer
NCT06079554 ·Status: RECRUITING
-
Relationship Between Standard Treatment Efficacy and The Tumor Microenvironment in Advanced Gastric Cancer
NCT04850716 ·Status: UNKNOWN
-
The Efficacy of Precision Treatment for Gastric Cancer Guided by Molecular Profiling
NCT04501887 ·Status: UNKNOWN
-
The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer
NCT03607656 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Helicobacter Pylori Eradication to Prevent Gastric Cancer
NCT01133951 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Machine Learning-driven Noninvasive Screening of Transcriptomics Liquid Biopsies for Early Diagnosis of Occult Peritoneal Metastases in Locally Advanced Gastric Cancer
NCT06478394 ·Status: RECRUITING
-
The Effect of Immunological Heterogeneity of Tumor Microenvironment in the Prognosis of Gastric Cancer
NCT04819958 ·Status: UNKNOWN
-
A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
NCT06452329 ·Status: COMPLETED
-
First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
NCT06727981 ·Status: RECRUITING